Literature DB >> 2720985

Lactate dehydrogenase isoenzyme patterns in serum of patients with metastatic liver disease.

Z Rotenberg1, I Weinberger, E Davidson, J Fuchs, D Harell, J Agmon.   

Abstract

Total lactate dehydrogenase (LD, EC 1.1.1.27) and LD isoenzymes were determined in serum of 170 patients with metastatic liver disease, 35 of whom had multiple metastatic sites. Overall, values of LD were above normal for 78% of the 170 patients. Half of the patients had an isomorphic pattern of LD isoenzymes (i.e., relative increase in all five isoenzymes); the other half had an increased LD-4,5 pattern, mostly a solitary increase in LD-5 only. Of those patients with normal LD values, 92% had the increased LD-4,5 pattern, whereas 70% of patients with LD values greater than 350 U/L had an isomorphic pattern of LD isoenzymes. All 35 patients with multiple metastatic sites had LD activity greater than 350 U/L; in the majority of them (74%) it was greater than 500 U/L; in 31 (89%), the increase was isomorphic. The diagnostic efficiency of the combined LD greater than 225 U/L (upper limit of normal) and increased LD-4,5 test results was much better than that of LD greater than 225 U/L alone (93% vs 74%). We conclude that serum LD and LD isoenzymes should be determined in every patient with suspected liver metastatic disease. The isomorphic pattern of LD isoenzymes is apparently associated with higher values for total LD and was common among the patients with multiple metastatic sites.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2720985

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  2 in total

1.  Differential liver protein expression during schistosomiasis.

Authors:  Marina Harvie; Thomas William Jordan; Anne Camille La Flamme
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

2.  Serological diagnosis of liver metastasis in patients with breast cancer.

Authors:  Rui Cao; Li-Ping Wang
Journal:  Cancer Biol Med       Date:  2012-03       Impact factor: 4.248

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.